Cargando…

High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma

Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10) as a predictive biomarker for first-line ICI therapy in patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Youngun, Yang, Hannah, Lee, Won Suk, Cheon, Jaekyung, Sang, Yun Beom, Kang, Beodeul, Chon, Hong Jae, Kim, Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158513/ https://www.ncbi.nlm.nih.gov/pubmed/37151396 http://dx.doi.org/10.7150/jca.81384

Ejemplares similares

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
por: Sang, Yun Beom, et al.
Publicado: (2022)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
por: Chon, Young Eun, et al.
Publicado: (2022)

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
por: Kim, Chan, et al.
Publicado: (2022)

High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer
por: Park, Hyung Soon, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
por: Cheon, Jaekyung, et al.
Publicado: (2023)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway
por: Kim, Jeong Hun, et al.
Publicado: (2021)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
por: Cheon, Jaekyung, et al.
Publicado: (2021)

The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
por: Kim, Han Sang, et al.
Publicado: (2022)

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
por: Lee, Sung Hwan, et al.
Publicado: (2023)

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
por: Lee, Won Suk, et al.
Publicado: (2020)

Association of baseline serum cholesterol with benefits of intensive blood pressure control
por: Wang, Xiaoqi, et al.
Publicado: (2023)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD
por: Jiang, Shenghua, et al.
Publicado: (2018)

IL-10 Gene Polymorphisms and IL-10 Serum Levels in Patients with Multiple Sclerosis in Lithuania
por: Masilionyte, Ugne, et al.
Publicado: (2022)

Combined Detection of Serum IL-10, IL-17, and CXCL10 Predicts Acute Rejection Following Adult Liver Transplantation
por: Kim, Nayoung, et al.
Publicado: (2016)

Correlation between serum inflammatory factors TNF-α, IL-8, IL-10 and Henoch-Schonlein purpura with renal function impairment
por: Yuan, Liangdong, et al.
Publicado: (2018)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

The effects of IL-10 gene polymorphism on serum, and gingival crevicular fluid levels of IL-6 and IL-10 in chronic periodontitis
por: Toker, Hulya, et al.
Publicado: (2018)

Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer
por: Feng, Lanyun, et al.
Publicado: (2018)

The Effect of Secreted IL-10 from Mesenchymal Stem Cell on Immune Checkpoint Molecules
por: Sari, Mutiara Indah, et al.
Publicado: (2023)

Serum IL-6 and IL-10 concentrations in bitches with pyometra undergoing ovariohysterectomy
por: Dąbrowski, Roman, et al.
Publicado: (2015)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
por: An, Ho Jung, et al.
Publicado: (2021)

Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible-Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China
por: Zhang, Renwen, et al.
Publicado: (2016)

Association of IL10, IL10RA, and IL10RB Polymorphisms with Benign Prostate Hyperplasia in Korean Population
por: Yoo, Koo Han, et al.
Publicado: (2011)

Serum Levels of Interleukin 10 (IL-10) in Patients with Type 2 Diabetes
por: Yaghini, N, et al.
Publicado: (2011)

The Gangwon Obesity and Metabolic Syndrome Study: Methods and Initial Baseline Data
por: Cho, Yoon Jeong, et al.
Publicado: (2022)

Influence of IL10 (rs1800896) Polymorphism and TNF-α, IL-10, IL-17A, and IL-17F Serum Levels in Ankylosing Spondylitis
por: Braga, Matheus, et al.
Publicado: (2021)

Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis
por: Rey, Imelda, et al.
Publicado: (2021)

The Benefits of Spiritual Diaries: A Mixed-Method Study in Korea
por: Kim, Suk-Sun, et al.
Publicado: (2021)

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Serum IL-10 as a marker of severe dengue infection
por: Malavige, Gathsaurie Neelika, et al.
Publicado: (2013)

Baseline Renal Function Predicts Hyponatremia in Liver Cirrhosis Patients Treated with Terlipressin for Variceal Bleeding
por: Kim, Sung Eun, et al.
Publicado: (2017)

Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response
por: El-Emshaty, Hoda Mohamed, et al.
Publicado: (2015)

Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy
por: Zhang, Lixia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_plqbbi2o13vgov0rig84effocm